Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 February 2006

Bifenthrin inhibits neurite outgrowth in differentiating PC12 cells.

Van Tran, Natalie Hoffman, Adaobi Mofunanaya, Stephen Pryor, Olutosin Ojugbele, Ashlea McLaughlin, Lydia Gibson, Josephine A. Bonventre, Katherine Flynn, Benjamin Weeks

Med Sci Monit 2006; 12(2): BR57-62 :: ID: 445228


Background: Bifenthrin is a third generation member of the synthetic pyrethroidfamily of insecticides. As a new pesticide within a relatively new class of pesticides, bifenthrin isconsidered relatively safe. Here, we used the PC12 neuronal cell line to examine the effect of bifenthrinon the formation of neurites and the potential developmental neurotoxicity of this pesticide. Material/Methods:PC12 cells were exposed to varying concentrations of technical grade bifenthrin or Ortho Home Defense[sup]®[/sup].Cell viability was determined using the AlmarBlue Toxicity Assay. Nontoxic concentrations of these chemicalswere concomitantly with nerve growth factor and neurite outgrowth was assessed. Results: Ortho Home Defense[sup]®[/sup]preparation reduced PC12 cell viability by approximately 50% and 70% at dilutions that correlate to bifenthrinconcentrations of 10[sup]-5[/sup] M and 10[sup]®[/sup] M, respectively. In contrast, technical grade bifenthrin, was nottoxic to PC12 cells at 10[sup]-3[/sup] M, which was the highest concentration tested that was soluble. At "nontoxic"concentrations of 10[sup]-7[/sup] M and 10[sup]-6[/sup] M, the Ortho Home Defense[sup]®[/sup] inhibited nerve growth factor-mediatedneurite outgrowth by 30% and 55% respectively. Furthermore the nontoxic concentrations of technical gradebifenthrin of 10[sup]-6[/sup] M and 10[sup]-3[/sup] M inhibited neurite outgrowth by approximately 35% and 75% respectively.Conclusions: These data suggest that the toxicity of the Ortho Home Defense[sup]®[/sup] preparation was dueto the "inert" additives in the preparation and not the bifenthrin itself. Further, these data suggestthat, even in the absence of overt toxicity, bifenthrin may have deleterious effects to developing nervoussystem.

Keywords: Cell Survival - drug effects, Insecticides - toxicity, Neurites - pathology, Neurotoxins - toxicity, Pyrethrins - toxicity

Add Comment 0 Comments


01 March 2024 : Editorial  

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia

Dinah V. Parums

DOI: 10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204


In Press

15 Jan 2024 : Clinical Research  

Comparison of Modified Shock Index and Shock Index for Predicting Massive Transfusion in Women with Primary...

Med Sci Monit In Press; DOI: 10.12659/MSM.943286  


15 Jan 2024 : Database Analysis  

Bibliometric Analysis of Brain Stimulation Technologies in Sleep Disorders

Med Sci Monit In Press; DOI: 10.12659/MSM.942687  

15 Jan 2024 : Clinical Research  

Clinical Outcomes of Arthroscopic Surgery in Patients with Gluteal Muscle Contracture: Single-Institution R...

Med Sci Monit In Press; DOI: 10.12659/MSM.942945  

17 Jan 2024 : Laboratory Research  

Impact of Auxiliary Features on Retention of Short Dental Crowns: An In-Vitro Analysis of Box and Groove Pr...

Med Sci Monit In Press; DOI: 10.12659/MSM.943401  

Most Viewed Current Articles

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387


17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799


14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990


01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952


Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750